Filing Details
- Accession Number:
- 0000899243-21-031120
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-02 20:34:24
- Reporting Period:
- 2021-08-02
- Accepted Time:
- 2021-08-02 20:34:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1786255 | Icosavax Inc. | ICVX | Pharmaceutical Preparations (2834) | I0 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1121404 | Sanofi | 54, Rue La Boetie Paris I0 75008 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock (Par Value, $0.0001) | Acquisiton | 2021-08-02 | 3,088,502 | $0.00 | 3,088,502 | No | 4 | C | Indirect | Through its wholly-owned subsidiary, Aventis Inc. |
| Common Stock (Par Value, $0.0001) | Acquisiton | 2021-08-02 | 66,667 | $15.00 | 3,155,169 | No | 4 | P | Indirect | Through its wholly-owned subsidiary, Aventis Inc. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | Through its wholly-owned subsidiary, Aventis Inc. |
| No | 4 | P | Indirect | Through its wholly-owned subsidiary, Aventis Inc. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock (par value, $0.0001) | Disposition | 2021-08-02 | 12,480,498 | $0.00 | 3,003,224 | $0.00 |
| Common Stock | Series B-1 Preferred Stock (par value, $0.0001) | Disposition | 2021-08-02 | 354,393 | $0.00 | 85,278 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
- Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc.
- The reporting person acquired additional shares in the Issuer's initial public offering.
Billionaire Hedge Funds
